Tekmira Pharmaceuticals Corp. has entered a licensing and collaboration agreement with Dicerna Pharmaceuticals for its lipid nanoparticle (LNP) delivery technology for exclusive use in Dicerna’s hyperoxaluria type 1 (PH1) development program.   Tekmira will receive $2.5 million upfront and $22 million in aggregate development milestones, plus a royalty on future PH1 sales. Also, under a supply agreement, Tekmira will provide clinical drug supply and regulatory support for the advancement o...